Karen S. Cheung Tung Shing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen S. Cheung Tung Shing has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Michael W. Parker
Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, VIC 3010, Australia
71 shared publications - Tracy L. Nero
Department of Biochemistry and Pharmacology, and ACRF Facility for Innovative Cancer Drug Discovery, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Australia
71 shared publications - Angel F. Lopez
Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia, Australia
69 shared publications - Sophie E. Broughton
Australian Cancer Research Foundation Rational Drug Discovery Centre, St. Vincent's Institute of Medical Research, Fitzroy, Victoria, Australia
69 shared publications - Urmi Dhagat
Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
69 shared publications - Timothy R. Hercus
The Centre for Cancer Biology, SA Pathology and the University of South Australia, Adelaide, South Australia 5000, Australia
67 shared publications
Latest Publications
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα P248 at the IL-3R assembly interface is critical for cell differentiation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα P248 at the IL-3R assembly interface is critical for cell differentiation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Summary of the key interactions in the IL-3R ternary complex in the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Summary of the key interactions in the IL-3R ternary complex in the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
The IL-3R dodecamer activates STAT1 to induce cell differentiation.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
The IL-3R dodecamer activates STAT1 to induce cell differentiation.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Key interactions between distinct residues in the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Key interactions between distinct residues in the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Enrichment of the IL-3R hexamer versus dodecamer gene signature in primitive normal and leukemic stem cells.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Enrichment of the IL-3R hexamer versus dodecamer gene signature in primitive normal and leukemic stem cells.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Data collection and refinement statistics for the IL-3R ternary complex crystal structure.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Data collection and refinement statistics for the IL-3R ternary complex crystal structure.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα/βc transcript and protein expression ratio in AML patient samples.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
IL3Rα/βc transcript and protein expression ratio in AML patient samples.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios lead to hexameric receptor assembly and augmented quiescence.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios lead to hexameric receptor assembly and augmented quiescence.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios and enforced hexamer signaling lead to reduced differentiation in in vivo engraftments.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Distinct Assemblies of Heterodimeric Cytokine Receptors Govern Stemness Programs in Leukemia
Increasing IL3Rα/βc ratios and enforced hexamer signaling lead to reduced differentiation in in vivo engraftments.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Distinct assemblies of heterodimeric cytokine receptors govern stemness programs in leukemia
IL3Rα/βc transcript and protein expression ratio in AML patient samples.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Distinct assemblies of heterodimeric cytokine receptors govern stemness programs in leukemia
IL3Rα/βc transcript and protein expression ratio in AML patient samples.